Our Tech

An engine built for the
scale of the problem

Drug design asks us to find possibility within almost unimaginable scientific complexity.
The Isomorphic Labs Drug Design Engine (IsoDDE) is our answer, bringing together multiple predictive and generative AI models to reach further across biology, types of medicine and disease areas – at the scale our mission demands.

Navigating a near‑infinite haystack

There are estimated to be around 1060 possible drug-like molecules – far more than scientists could ever make and test. We believe answers to many unsolved diseases lie somewhere within that immense chemical space. With AI, we have new ways to guide the search.

Rather than screening every possibility, IsoDDE can generate promising designs, predict their properties, and refine them computationally before scientists decide what to make and test in the lab.

“The interesting problem goes beyond predicting what one molecule will do to one target. It’s whether you can use those predictions to navigate an impossibly large space, and find promising chemistry worth pursuing.”
Alden Hung
Alden Hung
AI Research Scientist

Building beyond AlphaFold

AlphaFold demonstrated that AI could crack a problem in biology that had defied decades of scientific endeavour: predicting the 3D structure of proteins. That breakthrough inspired the founding of Isomorphic Labs in 2021. In 2024, it earned our founder and chief executive, Sir Demis Hassabis, a Nobel prize in chemistry.
That same year, scientists at Iso and Google DeepMind released a paper announcing the development of AlphaFold 3, which predicts the structures and interactions of proteins, DNA, RNA, ligands and other biomolecules.
But designing a medicine demands more than structure prediction: understanding where and how a molecule might bind, how strongly, what properties it will have and how it might behave in a complex biological system.

Our drug design engine

General by design

IsoDDE is designed to generalise across novel biological and chemical systems, therapeutic areas and drug modalities. One engine, applied again and again.

“A model that generalises opens up entirely new possibilities: new chemistry, new targets, new drug design opportunities.”

Kathryn Tunyasuvunakool, AI Research Scientist

Setting new benchmarks

A technical paper on Iso’s drug design engine reports state-of-the-art performance across three core problems in AI-driven drug discovery:

  • Structure prediction: More than doubled AlphaFold 3’s accuracy on the most difficult novel systems tested
  • Binding affinity prediction: Outperformed existing deep-learning and industry-standard physics-based methods
  • Blind pocket identification: Outperformed P2Rank by 1.4×

“Novel systems are where you really test generalisation. Drug discovery constantly takes you beyond what is already known, so we need models that remain useful when the biology or chemistry is unfamiliar.”

Adrian Stecula, Research Scientist

Read the technical paper

No step in isolation

IsoDDE brings machine learning and drug discovery together from the outset – drawing on diverse data and the large-scale computing power needed to learn from it.
It’s built for the whole process: from designing a molecule to developing a potential medicine, with each step informing the next.

Already at work

Our scientists use IsoDDE across a growing portfolio of internal and partnered programs, moving promising ideas toward potential medicines.

Explore our partnerships

“When you build the platform and the drug programs together from the beginning, the scientists who understand the problems are talking directly to the technologists who can work on the solutions. That’s very different from building technology first and then asking where it might be useful.”

Sarah Skerratt
Chief research officer

“Computation can take us into parts of chemical space we might never have explored, and then chemistry gets its turn. A molecule either behaves as we hoped or teaches us something new. Either way, we’re moving forward.”

Franca Klingler
Research Scientist
our leadership

Meet the Isos powering our progress

OUR OPPORTUNITIES

Join our growing team of Isos